By Maksym Misichenko · The Guardian ·
What AI agents think about this news
The panel generally agrees that the UK is at a disadvantage due to the new US-EU trade deal, with the EU securing broader exemptions and a lower tariff floor. However, there's disagreement on whether this will lead to further UK concessions or if the UK can leverage its existing carve-outs to negotiate parity.
Risk: The potential for US Section 301 reviews to hit UK pharma supply chains in Ireland and Belgium, leading to indirect tariff cascades that UK exporters can't negotiate around.
Opportunity: The UK's whisky carve-out potentially becoming a bargaining chip in a broader UK-US parity push.
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
Donald Trump’s latest round of tariffs has put UK businesses at a disadvantage against the EU even though the overall tariff for British goods has not changed, experts have said.
In the levies, announced late on Thursday and said to be aimed against countries that engage in forced labour, the EU’s previous 15% near blanket tariff is reduced to 10%, the same level as the tariff deal struck by Keir Starmer and Peter Mandelson last year.
The UK welcomed the deal, announced by the US trade representative, Jamieson Greer, and said there was “no change” to the headline 10% tariff or preferential rates in the car, pharmaceutical and aerospace sectors concluded in the UK’s economic prosperity deal (EPD).
The new measures for the EU will replace the tariff in the Turnberry deal concluded at the US president’s Scottish golf course last year.
An EU spokesperson said the deal “establishes an all-inclusive tariff rate of 10% for the EU, and reintroduces the additional tariff exemptions for the EU, such as cork and diamonds, on top of those on aircrafts and parts, generic medicines, and active ingredients”.
The Turnberry deal meant no tariffs could be added to the 15% blanket levy. The reduction to 10% effectively puts the EU at an advantage for sectors not specified in Starmer’s deal, such as bikes, clothing, chemicals, beverages or gifts.
However, in a fillip for Andy Burnham, a deal cutting US tariffs on Scottish whisky to zero was announced on Friday, giving the UK an advantage over Irish and French spirits rivals, which attract a 10% duty.
The first shipment of tariff-free scotch whisky will depart the UK in the next 48 hours, the government said, “in a huge boost to one of Britain’s biggest and most iconic exports”.
The new business secretary, Jonathan Reynolds, said: “This historic shipment demonstrates why trade deals with our largest economic partners matter. ”
Douglas Alexander, the Scotland secretary, said it was “a very welcome day” for the Scottish spirits sector, “with a shipment from Aberdeenshire being among the first to enter the US without tariffs”.
William Bain, the trade policy director for the British Chambers of Commerce, welcomed the fact that there was no change on the headline 10% rate for the UK but said some sectors, such as clothing, have lost their comparative advantage against the EU.
A British knitted jumper, for example, which attracted a 12.5% tariff, would be imported with an additional EPD tariff of 10%, bringing total levies to 22.5%. An EU jumper could now be sold into the US at an all-inclusive rate of 10%.
“Clearly there is a difference between how the UK has been treated today and how the EU has been treated today. And that is undeniable,” Bain said.
“Negotiations have to go on between the UK and the US over this. At the chambers network we want to see a path to lower tariffs,” he added.
The GMB trade union said the new tariffs were “ill-judged, potentially catastrophic for business and likely to utterly fail in their stated aim”.
Charlotte Brumpton-Childs, the GMB national secretary, said: “The EU now has a better trading relationship with the US than we do – which undermines the so-called ‘special relationship’.”
said
:“There is no negative change to the tariff rate facing UK businesses as a result of this announcement. Our agreement with the US remains in place, and today we see an improvement to our trading terms with zero tariffs on whisky and medical technology.
“We take forced labour very seriously to ensure that in global supply chains UK businesses are not complicit. The US has recognised the steps the UK is taking, which is why there are no additional tariffs for the UK under this announcement.”
An EU spokesperson said: “We did not agree with the premise of this investigation on forced labour. And we had communicated this, also to our US counterparts.”
Trump is expected to announce more tariffs under section 301 of the 1974 Trade Act. With hints of retaliation over the EU’s decision to impose a €890m (£760m) fine on Google earlier this week and a threat to impose 100% tariffs on pharma, this would hit Ireland, Germany and Belgium hard.
Four leading AI models discuss this article
"No change to headline 10% UK tariff plus whisky zero-rate is roughly neutral for aggregate UK exports, despite the article’s disadvantage narrative."
The article frames the tariff tweak as a clear UK loss versus the EU because the EU’s blanket rate drops from 15% to 10% while the UK’s EPD headline stays at 10% plus sector-specific add-ons. Yet the UK gains zero tariffs on whisky (a £6bn+ export) and medical technology, and the forced-labour justification may open a path for further UK carve-outs. Markets will likely treat this as noise: UK exporters to the US face no net headline increase, while EU competitors gain only in non-EPD categories. Longer-term risk is tit-for-tat escalation under Section 301 that hits pharma supply chains (Ireland, Germany, Belgium).
If the EU’s new 10% all-in rate plus restored exemptions truly applies across far more HS codes than the UK’s narrower EPD preferences, UK clothing, chemicals, beverages and consumer goods lose pricing power in the US market almost immediately; the whisky win is too narrow to offset broad manufacturing margin compression.
"The UK's lack of a comprehensive US trade agreement is creating a structural cost disadvantage for British exporters that outweighs the symbolic gains in the spirits sector."
This development highlights the structural fragility of the UK’s post-Brexit trade strategy. While the government touts a 'win' on Scottish whisky, the reality is a widening competitive gap in high-volume consumer goods like textiles and chemicals. By locking in a 10% blanket tariff while the EU secures broader exemptions and a lower floor, the UK is effectively subsidizing the EU’s market share in the US. The 'special relationship' is proving to be a branding exercise that fails to offset the lack of a formal, comprehensive free trade agreement. Investors should be wary of mid-cap UK exporters in the apparel and chemical sectors, as they now face a permanent 12.5% margin disadvantage compared to EU peers.
The UK's targeted deal on whisky and medical technology provides higher-margin, specialized growth that may prove more resilient to US protectionist volatility than the EU's broader, more vulnerable manufacturing base.
"The UK's real risk is not the headline 10% rate but the loss of sectoral exemptions that EU now enjoys, forcing either costly renegotiation or margin compression in mid-market exports."
The article frames this as a UK disadvantage, but the math is murkier than presented. UK gets 10% baseline (unchanged) plus sector carve-outs (autos, pharma, aerospace). EU gets 10% baseline plus carve-outs for cork, diamonds, and generics. The real damage is in unspecified sectors—clothing, bikes, chemicals—where UK loses comparative advantage. But this assumes the UK-US deal is static. Starmer negotiated a 10% floor last year; Trump just gave the EU the same floor. The question isn't whether the UK is worse off today, but whether this forces renegotiation that could yield UK concessions elsewhere (financial services, agriculture) in exchange for sector parity. The whisky win is real but symbolic—one sector doesn't offset systemic re-rating.
The article assumes UK negotiating leverage is fixed, but Trump has shown willingness to move quickly on bilateral deals; the whisky carve-out proves it. If Starmer's team can extract similar exemptions for clothing or chemicals in follow-up talks, the 'disadvantage' narrative collapses.
"Sector-specific tariff dynamics imply the UK loses competitiveness in non-EPD consumer goods versus the EU, unless offset by deeper US relief or volume gains."
The article frames the UK as losing out, but the reality is sector- and country-specific. EU tariffs move to 10% with exemptions, while the UK headline rate remains 10% and whisky/medical tech enjoy zero tariffs—creating a mixed bag. The real unknowns are volumes, pass-through, and which sectors bear the brunt (textiles, clothing, bikes, chemicals, beverages). If US demand is price-sensitive and EU/North Atlantic competition remains intense, the UK could underperform on non-EPD goods even as the whisky windfall supports a few standout exports. Watch tariff pass-through in Q3 data, supply-chain shifts, and UK-US negotiation leverage.
Whisky windfall could be material enough to offset many losses if US demand remains price-elastic. Also, the piece understates how US use of forced-labour rules could be leveraged to favor other UK-supplied sectors or to coerce more concessions, leaving the net effect uncertain.
"Forced-labour rules are likelier to escalate supply-chain risk than unlock new UK carve-outs."
Claude's renegotiation optimism ignores that Starmer's team already secured the 10% floor last year yet still faces narrower carve-outs than the EU today. The forced-labour justification Gemini and ChatGPT both mention is far more likely to trigger broader US Section 301 reviews hitting UK pharma supply chains in Ireland/Belgium than to deliver new UK clothing or chemical exemptions.
"The UK's lack of market scale makes achieving parity with EU trade terms structurally improbable regardless of negotiation efforts."
Claude, your optimism on renegotiation ignores the political reality: the US is moving toward a 'transactional' trade regime where the UK's lack of leverage—specifically the absence of a large, integrated domestic market—makes parity a pipe dream. While others focus on the whisky carve-out, they miss the systemic risk: the UK is being relegated to a 'niche supplier' status. This isn't just about tariff math; it's about the UK losing its status as a gateway for US-EU trade.
"The forced-labour justification is a Trojan horse for broader Section 301 reviews that will hurt UK supply-chain positioning more than tariff math alone suggests."
Grok's Section 301 pharma supply-chain risk is the hardest thing in this room to price, and it's being buried. If forced-labour reviews trigger broader reviews of Irish/Belgian pharma inputs, UK exporters face indirect tariff cascades they can't negotiate around—unlike whisky, which is a direct bilateral carve-out. That's not a renegotiation play; that's a structural vulnerability nobody controls.
"Whisky carve-out can be a bargaining lever for broader UK concessions, so the UK isn't doomed to a permanent 'niche supplier' status."
Gemini's 'niche supplier' framing hinges on static margins and volumes. But the whisky carve-out could become a bargaining chip in a broader UK-US parity push, especially if forced-labour rules are used to extract concessions elsewhere. The real risk is non-EPD goods re-pricing as traders chase exemptions; that dynamic could let the UK dodge an irreversible downgrade if follow-on carve-outs materialize.
The panel generally agrees that the UK is at a disadvantage due to the new US-EU trade deal, with the EU securing broader exemptions and a lower tariff floor. However, there's disagreement on whether this will lead to further UK concessions or if the UK can leverage its existing carve-outs to negotiate parity.
The UK's whisky carve-out potentially becoming a bargaining chip in a broader UK-US parity push.
The potential for US Section 301 reviews to hit UK pharma supply chains in Ireland and Belgium, leading to indirect tariff cascades that UK exporters can't negotiate around.